ReviewCureus2026
Short-Term Clinical and Immunologic Outcomes Conditional on SVR12 in Hepatitis C Virus-Associated Cryoglobulinemic Vasculitis Treated With Direct-Acting Antivirals: A Systematic Review and Meta-Analysis.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In contemporary clinical practice, direct-acting antiviral therapy (DAA) produces high rates of sustained virologic response (SVR) among patients with hepatitis C virus infection; however, short-term clinical and immunologic outcomes following viral eradication in HCV-associated cryoglobulinemic vasculitis remain incompletely characterized, particularly among patients who have already achieved SVR12. A systematic review and meta-analysis was performed to evaluate short-term outcomes conditional on achieving SVR12 among patients with symptomatic HCV-associated cryoglobulinemic vasculitis treated with interferon-free DAA therapy. EMBASE and PubMed were searched from inception through January 2026, and two reviewers independently screened studies and extracted data. Pooled proportions of complete clinical response, partial clinical response, and complete immunologic response at the time of SVR12 were calculated using random-effects models. Eighteen observational studies were included. Among patients who achieved SVR12, the pooled proportion of complete clinical response was 64.8% (95% CI: 49.6%-79.3%), while partial clinical response occurred in 23.8% (95% CI: 18.3%-30.4%). Complete immunologic response was observed in 43.9% of patients (95% CI: 36.6%-51.5%). Substantial heterogeneity was observed for clinical outcomes reflecting differences across observational cohorts, whereas heterogeneity was lower for immunologic response. In conclusion, among patients with HCV-associated cryoglobulinemic vasculitis who achieved SVR12 with DAA therapy, short-term clinical improvement was common, although complete immunologic normalization was less frequent. These findings provide clinically relevant prognostic information regarding early expectations following viral eradication, while highlighting that longer-term durability of response requires ongoing evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.